N
137.67
3.36 (2.50%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Bullish | Bullish |
Stockmoo Score
0.1
|
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Growth |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dsm Capital Partners Llc | 31 Mar 2024 | 1,136,002 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 219.00 (Oppenheimer, 59.08%) | Buy |
| Median | 173.00 (25.66%) | |
| Low | 128.00 (BMO Capital, -7.02%) | Hold |
| Average | 170.54 (23.88%) | |
| Total | 10 Buy, 3 Hold | |
| Avg. Price @ Call | 142.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 29 Aug 2024 | 128.00 (-7.02%) | Hold | 128.43 |
| Cantor Fitzgerald | 29 Aug 2024 | 155.00 (12.59%) | Buy | 128.43 |
| 25 Jul 2024 | 155.00 (12.59%) | Buy | 146.10 | |
| HC Wainwright & Co. | 29 Aug 2024 | 190.00 (38.01%) | Buy | 128.43 |
| Piper Sandler | 29 Aug 2024 | 159.00 (15.49%) | Buy | 128.43 |
| RBC Capital | 29 Aug 2024 | 136.00 (-1.21%) | Hold | 128.43 |
| 02 Aug 2024 | 143.00 (3.87%) | Hold | 153.14 | |
| Jefferies | 19 Aug 2024 | 189.00 (37.28%) | Buy | 148.24 |
| Baird | 02 Aug 2024 | 180.00 (30.75%) | Buy | 153.14 |
| Barclays | 02 Aug 2024 | 180.00 (30.75%) | Buy | 153.14 |
| Citigroup | 02 Aug 2024 | 158.00 (14.77%) | Hold | 153.14 |
| Guggenheim | 02 Aug 2024 | 180.00 (30.75%) | Buy | 153.14 |
| Oppenheimer | 02 Aug 2024 | 219.00 (59.08%) | Buy | 153.14 |
| Morgan Stanley | 12 Jul 2024 | 170.00 (23.48%) | Buy | 147.43 |
| 12 Jun 2024 | 160.00 (16.22%) | Buy | 134.62 | |
| JP Morgan | 10 Jul 2024 | 173.00 (25.66%) | Buy | 147.12 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2024 | Announcement | Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia |
| 28 Aug 2024 | Announcement | Neurocrine Biosciences to Participate at Investor Conferences in September |
| 07 Aug 2024 | Announcement | Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference |
| 01 Aug 2024 | Announcement | Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance |
| 18 Jul 2024 | Announcement | Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing |
| 11 Jul 2024 | Announcement | Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results |
| 01 Jul 2024 | Announcement | Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |